BWH Vascular Surgery (@brighamvascular) 's Twitter Profile
BWH Vascular Surgery

@brighamvascular

Official Twitter account of the Division of Vascular and Endovascular Surgery at Brigham and Women's Hospital

ID: 1346827332363800578

linkhttps://www.brighamandwomens.org/surgery/vascular-and-endovascular-surgery calendar_today06-01-2021 14:34:19

148 Tweet

676 Followers

291 Following

BWH Vascular Surgery (@brighamvascular) 's Twitter Profile Photo

Congratulations to Mohamad A Hussain MD and his research team for being awarded a two-year grant from the Brigham Heart and Vascular Center for their work with anti-inflammatory therapies to reduce major adverse CV and limb events in patients with PAD CSPH Brigham and Women's Hospital

Congratulations to <a href="/ma_hussainMD/">Mohamad A Hussain MD</a> and his research team for being awarded a two-year grant from the Brigham Heart and Vascular Center for their work with anti-inflammatory therapies to reduce major adverse CV and limb events in patients with PAD <a href="/CSPH_BWH/">CSPH</a> <a href="/BrighamWomens/">Brigham and Women's Hospital</a>
NEJM (@nejm) 's Twitter Profile Photo

In a randomized trial of patients with limb ischemia, those assigned to bypass surgery as compared with endovascular therapy as an initial strategy had fewer adverse limb events or all-cause death at a median of 2.7 years. #AHA22 nej.md/3U5wZ5w

In a randomized trial of patients with limb ischemia, those assigned to bypass surgery as compared with endovascular therapy as an initial strategy had fewer adverse limb events or all-cause death at a median of 2.7 years. #AHA22 nej.md/3U5wZ5w
Mohamad A Hussain MD (@ma_hussainmd) 's Twitter Profile Photo

Results of the Humacyte V007 Trial are out! #ATEV (Acellular Tissue Engineered Vessel) was superior to #AVF in #ESKD patients on #HD, particularly in high-risk patients: #females, #diabetics & #obese. Infection similary low in both groups. Exciting potential option in #HDaccess

Results of the <a href="/humacyte/">Humacyte</a> V007 Trial are out! #ATEV (Acellular Tissue Engineered Vessel) was superior to #AVF in #ESKD patients on #HD, particularly in high-risk patients: #females, #diabetics &amp; #obese. Infection similary low in both groups. Exciting potential option in #HDaccess